zanzalintinib + nivolumab

The combination of **zanzalintinib** (a novel, potent, oral small molecule tyrosine kinase inhibitor targeting multiple receptors including MET, AXL, VEGF, and MER) and **nivolumab** (a monoclonal antibody immune checkpoint inhibitor of PD-1) is being investigated for the treatment of advanced or metastatic renal cell carcinoma (RCC)[1][3][5]. Zanzalintinib inhibits multiple pathways involved in tumor growth and angiogenesis, while nivolumab works by enhancing anti-tumor immunity through PD-1 blockade[1][3]. Clinical studies such as STELLAR-002 and STELLAR-304 report a promising overall response rate (63%) and manageable safety profile in untreated stage 4 RCC[1][3][5].

Brand names

ZanzalintinibOpdivoXL092 + nivolumab

Other names

zanzalintinib plus nivolumabXL092 plus nivolumabXL-092 plus nivolumabXL 092 plus nivolumab